Sources of Multidrug Resistance in Patients With Previous Isoniazid-Resistant Tuberculosis Identified Using Whole Genome Sequencing: A Longitudinal Cohort Study
Open Access
- 15 November 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 71 (10), E532-E539
- https://doi.org/10.1093/cid/ciaa254
Abstract
Background. Meta-analysis of patients with isoniazid-resistant tuberculosis (TB) given standard first-line anti-TB treatment indicated an increased risk of multidrug-resistant TB (MDR-TB) emerging (8%), compared to drug-sensitive TB (0.3%). Here we use whole genome sequencing (WGS) to investigate whether treatment of patients with preexisting isoniazid-resistant disease with first-line anti-TB therapy risks selecting for rifampicin resistance, and hence MDR-TB. Methods. Patients with isoniazid-resistant pulmonary TB were recruited and followed up for 24 months. Drug susceptibility testing was performed by microscopic observation drug susceptibility assay, mycobacterial growth indicator tube, and by WGS on isolates at first presentation and in the case of re-presentation. Where MDR-TB was diagnosed, WGS was used to determine the genomic relatedness between initial and subsequent isolates. De novo emergence of MDR-TB was assumed where the genomic distance was 5 or fewer single-nucleotide polymorphisms (SNPs), whereas reinfection with a different MDR-TB strain was assumed where the distance was 10 or more SNPs. Results. Two hundred thirty-nine patients with isoniazid-resistant pulmonary TB were recruited. Fourteen (14/239 [5.9%]) patients were diagnosed with a second episode of TB that was multidrug resistant. Six (6/239 [2.5%]) were identified as having evolved MDR-TB de novo and 6 as having been reinfected with a different strain. In 2 cases, the genomic distance was between 5 and 10 SNPs and therefore indeterminate. Conclusions. In isoniazid-resistant TB, de novo emergence and reinfection of MDR-TB strains equally contributed to MDR development. Early diagnosis and optimal treatment of isoniazid-resistant TB are urgently needed to avert the de novo emergence of MDR-TB during treatment.Funding Information
- Wellcome Trust (081814/Z/06/Z)
- Wellcome Trust Intermediate Fellowship in Public Health and Tropical Medicine (206724/Z/17/Z)
- Wellcome Trust Major Overseas Program (106680/B/14/Z)
- Agency for Science, Technology and Research
- National Health and Medical Research Council (APP1056689)
This publication has 28 references indexed in Scilit:
- Advances in clinical trial design for development of new TB treatments—Translating international tuberculosis treatment guidelines into national strategic plans: Experiences from Belarus, South Africa, and VietnamPLoS Medicine, 2019
- The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB eraThe Lancet Respiratory Medicine, 2018
- Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosisBMC Infectious Diseases, 2018
- Transmission is a Noticeable Cause of Resistance Among Treated Tuberculosis Patients in Shanghai, ChinaScientific Reports, 2017
- Use of whole-genome sequencing to distinguish relapse from reinfection in a completed tuberculosis clinical trialBMC Medicine, 2017
- Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistanceNature Genetics, 2017
- Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2016
- Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-NatalPLoS Medicine, 2015
- Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosisThe Lancet Infectious Diseases, 2010
- Exogenous Reinfection as a Cause of Multidrug‐Resistant and Extensively Drug‐Resistant Tuberculosis in Rural South AfricaThe Journal of Infectious Diseases, 2008